CAR-T cell therapy for B-cell acute lymphoblastic leukemia in patients unable to tolerate strong chemotherapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that have been modified to find and kill cancer cells with a marker called CD19. It is for adults newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma who cannot handle strong chemotherapy due to health reasons.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have been newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma and your doctor has said you cannot have strong chemotherapy.
- Your cancer cells must have a marker called CD19 (confirmed by a lab test).
- You must be well enough to perform daily activities (ECOG score 0-2).
- Your major organs (liver, kidneys, lungs, heart) must be working fairly well.
- You cannot have other serious illnesses like active infections, autoimmune diseases, or other advanced cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This early-phase trial tests a personalized cancer treatment using your own immune cells (called CAR T-cells) to target and kill leukemia cells that have a specific marker (CD19). It may be an option for adults with B-cell acute lymphoblastic leukemia (B-ALL) who haven't had this type of therapy before.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma that has come back or did not respond to previous treatments.
Hear when a new B Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.